AOD-9604 Overdose and Accidental Excess Dose

What Is AOD-9604 and Why Does Overdose Risk Matter?

AOD-9604 is a synthetic peptide derived from the C-terminal region of human growth hormone. Compounding pharmacies prepare it under FDA Section 503A guidelines for subcutaneous injection, typically targeting adipose tissue modulation. Because no FDA-approved labeling exists, patients receive dosing instructions from their prescribing clinician rather than a standardized package insert. This makes dosing errors more likely than with commercially manufactured drugs.

How AOD-9604 Differs from Full-Length Growth Hormone

The peptide consists of amino acids 176-191 of the hGH sequence, with a tyrosine residue replacing the native amino acid at the N-terminus. Heffernan et al. Demonstrated in 2001 that this fragment stimulates lipolysis in adipose tissue without activating the growth hormone receptor [1]. That distinction is the single most important safety consideration in an overdose scenario. Full-length hGH excess causes acromegaly, insulin resistance, and cardiomegaly, but AOD-9604's inability to bind the GH receptor means supra-pharmacologic doses do not trigger the same downstream IGF-1 surge [2].

Why Dosing Errors Occur with Compounded Peptides

Compounded peptides are dispensed as lyophilized powder requiring reconstitution with bacteriostatic water. Calculation mistakes during reconstitution represent the most frequent source of excess dosing. A patient who adds half the intended volume of diluent effectively doubles the concentration per unit drawn, a pattern the FDA has flagged in compounding safety communications [3]. Insulin syringes calibrated in units rather than micrograms add another layer of confusion.

How AOD-9604 Works: Mechanism Relevant to Toxicity

Understanding AOD-9604's pharmacology clarifies why overdose consequences differ from those of intact growth hormone or other growth-hormone-releasing peptides.

Lipolytic Pathway Activation

AOD-9604 stimulates beta-3 adrenergic receptor-mediated lipolysis in white adipose tissue. The original animal work by Heffernan et al. Showed that the fragment increased fat oxidation in ob/ob mice without changing lean body mass or serum IGF-1 levels [1]. A separate study confirmed that the lipolytic effect depends on a cyclic AMP pathway independent of the growth hormone receptor signaling cascade [4]. At excess doses, this pathway could theoretically increase circulating free fatty acids, but no published human trial has reported clinically significant dyslipidemia from acute AOD-9604 overexposure.

Absence of GH-Receptor Signaling

Full-length hGH binds GH receptors in the liver, triggering JAK2-STAT5 phosphorylation and IGF-1 synthesis [5]. The truncated AOD-9604 molecule lacks the N-terminal domain required for this receptor engagement. In the Phase IIb trial data summarized by Metabolic Pharmaceuticals, participants receiving up to 1 mg/day of oral AOD-9604 for 24 weeks showed no statistically significant changes in fasting glucose, insulin, or IGF-1 compared to placebo [6]. This absence of metabolic disruption at chronic supra-therapeutic doses provides indirect reassurance about acute overdose safety.

Rapid Clearance Kinetics

Like most linear peptides under 2 kDa, AOD-9604 is subject to rapid enzymatic degradation by serum peptidases and renal filtration [7]. The estimated half-life is under 60 minutes. Rapid clearance means that even a significant excess dose is substantially eliminated within 3 to 4 hours, limiting the window of any pharmacologic effect.

Recognizing an AOD-9604 Overdose

No formal overdose case series exists for AOD-9604. The symptom profile below is extrapolated from adverse events reported in clinical trials, post-market surveillance of compounded peptides, and the known pharmacology.

Expected Mild Symptoms

Most patients who accidentally inject two or three times the intended dose will experience injection-site reactions (erythema, swelling, localized pain), mild headache, or transient nausea. These effects parallel the adverse-event profile reported in growth-hormone-fragment research at standard doses [1] and are self-limiting within hours.

Symptoms Warranting Medical Evaluation

Persistent vomiting, significant dizziness, tachycardia, or chest discomfort after a peptide injection should prompt medical evaluation regardless of the suspected agent. While these symptoms have not been specifically attributed to AOD-9604 excess in published literature, the FDA advises treating any adverse reaction to a compounded product as reportable through MedWatch [8]. Allergic reactions to excipients (mannitol, bacteriostatic water preservatives) can mimic overdose symptoms and may require epinephrine.

Symptoms That Are Unlikely

Hypoglycemia, fluid retention, carpal tunnel syndrome, and joint pain are hallmarks of exogenous GH excess [9]. Because AOD-9604 does not activate the GH receptor, these symptoms are not expected even at very high doses. If a patient presents with these findings after injecting what they believe is AOD-9604, product contamination or mislabeling should be suspected, and the vial should be retained for third-party analytical testing [10].

Immediate Steps After an Accidental Excess Dose

A structured response reduces anxiety and captures information that clinicians need.

Step 1: Stop and Document

Discontinue further dosing immediately. Record the estimated dose injected (in micrograms), the time of injection, the reconstitution volume used, and the lot number on the vial. This information helps Poison Control or the emergency department assess risk.

Step 2: Contact Poison Control or Your Prescriber

Call the American Association of Poison Control Centers at 1-800-222-1222. Trained specialists can triage peptide exposures. Your prescribing clinician's office should also be notified, as they may want follow-up labs (fasting glucose, IGF-1) to confirm the absence of GH-receptor effects.

Step 3: Monitor for 4 Hours

Given the sub-60-minute half-life, most pharmacologic activity will have ceased within 3 to 4 hours. During this period, stay hydrated and monitor for headache, nausea, or injection-site changes. If symptoms worsen rather than improve after 4 hours, proceed to an emergency department.

Step 4: Report to the FDA

Adverse events involving compounded drugs should be submitted through the FDA MedWatch portal [8]. These reports feed into the safety database that the FDA uses to evaluate whether a compounded substance warrants additional restrictions. Reporting takes approximately 10 minutes online.

Clinical Management in an Emergency Setting

Emergency physicians encountering a patient who reports AOD-9604 overdose should apply standard toxicologic principles for peptide exposures.

Assessment and Monitoring

Initial workup should include a basic metabolic panel (to check glucose and electrolytes), a 12-lead ECG, and vital-sign monitoring. The Endocrine Society's clinical practice guidelines on GH use emphasize that IGF-1 measurement can help distinguish between GH-receptor-mediated effects and non-GH-receptor peptide activity [11]. A normal IGF-1 level effectively rules out GH-pathway toxicity.

Supportive Care

No antidote for AOD-9604 exists. Management is entirely supportive: IV fluids for dehydration from vomiting, ondansetron (4 mg IV) for persistent nausea, and standard anaphylaxis protocols if allergic signs appear. Activated charcoal is not indicated because the route of exposure is subcutaneous rather than oral [12]. The National Capital Poison Center provides a triage algorithm for injectable drug exposures that applies to peptide cases.

When to Consider Product Contamination

If the clinical picture includes symptoms inconsistent with AOD-9604 pharmacology (severe hypoglycemia, rapid-onset edema, acromegalic signs), the injected product may contain full-length hGH or another bioactive peptide. The FDA has issued multiple warning letters to compounding pharmacies for labeling inaccuracies and contamination [13]. In such cases, retain the vial and request independent laboratory analysis.

Long-Term Considerations After an Overdose Event

A single accidental excess dose of AOD-9604 is unlikely to cause lasting harm based on available evidence. The Phase IIb oral trial administered doses well above the typical subcutaneous research dose for 24 weeks without serious adverse events attributable to the peptide [6].

Resuming Therapy

If the prescribing clinician decides that AOD-9604 therapy should continue, resumption at the originally prescribed dose is appropriate after a 24-to-48-hour washout. This interval provides ample clearance time given the peptide's short half-life and allows monitoring for any delayed effects.

Preventing Future Errors

Reconstitution errors account for most peptide dosing mistakes. Patients should use a standardized reconstitution calculator and verify their math with their pharmacist before drawing the first dose from a new vial [14]. Pre-filled syringes prepared by the compounding pharmacy eliminate reconstitution math entirely and represent the lowest-risk delivery format.

AOD-9604 Overdose Risk-Stratification Framework

Clinicians can categorize accidental AOD-9604 excess doses into three tiers:

Tier 1 (Low risk): Up to 2x the prescribed dose. Expected outcome: mild or no symptoms. Action: stop dosing, observe at home for 4 hours, resume next scheduled dose.

Tier 2 (Moderate risk): 3x to 5x the prescribed dose, or any dose in a patient with a cardiovascular or hepatic comorbidity. Expected outcome: possible nausea, headache, injection-site reaction. Action: call Poison Control, hold next 1 to 2 doses, obtain basic metabolic panel if symptoms persist.

Tier 3 (Higher risk): Greater than 5x the prescribed dose, unknown quantity injected, or symptoms inconsistent with AOD-9604 pharmacology. Expected outcome: unpredictable, possible product contamination. Action: emergency department evaluation, retain vial for analysis, file MedWatch report [8].

AOD-9604 vs. Full-Length hGH: Overdose Comparison

| Parameter | AOD-9604 (HGH Fragment 176-191) | Full-Length hGH (Somatropin) | |---|---|---| | GH receptor binding | None [1] | Yes, high affinity [5] | | IGF-1 elevation at excess dose | Not observed [6] | Dose-dependent, significant [11] | | Hypoglycemia risk | Not expected | Reported at supra-therapeutic doses [9] | | Fluid retention / edema | Not expected | Common at high doses [9] | | Carpal tunnel risk | Not expected | Well-documented with chronic excess [9] | | Half-life | <60 minutes [7] | 2-3 hours (SC injection) [11] | | Antidote | None; supportive care | None; supportive care | | Reportable to FDA | Yes, via MedWatch [8] | Yes, via MedWatch |

Regulatory Context: Why Overdose Data Is Limited

AOD-9604 has not completed the FDA approval process, which means no standardized prescribing information, black-box warnings, or post-marketing surveillance infrastructure exists for this peptide. The compound was granted GRAS (Generally Recognized as Safe) status by the FDA in 2014 for oral use as a food ingredient, but this designation does not apply to injectable formulations [15]. The absence of Phase III trial data means that overdose thresholds remain undefined by regulatory standards.

Compounding pharmacies that prepare AOD-9604 operate under Section 503A of the FD&C Act, which exempts them from standard new-drug-application requirements but does not exempt them from current Good Manufacturing Practice inspections [3]. Patients should verify that their pharmacy holds state board accreditation and voluntarily complies with PCAB or USP 797 standards [13].

The Endocrine Society has not published specific guidelines on peptide-fragment overdose management, though their 2019 growth hormone therapy guidelines provide the closest clinical framework for assessing GH-axis perturbation in overdose contexts [11].